



NEWS RELEASE

Defilovir™ is an effective treatment against Ebola virus infection in two animal models; study results published in Journal of Bioterrorism & Biodefense.

Web Site Release

November 15, 2011

Toronto - Defyurus Inc. today announced the publication in the Journal of Bioterrorism and Biodefense of successful Defilovir™ treatment of Ebola virus infections in mice and guinea pigs. These studies were a collaborative effort among the National Microbiology Laboratory (NML) of the Public Health Agency of Canada, the University of Manitoba and Defyurus. Defilovir™ is a combination drug consisting of two components: an Ebola vaccine (Ad5-optZGP from NML) and a broad spectrum antiviral and immune stimulator (DEF201 from Defyurus). Animals treated with Defilovir™ after Ebola infection showed an enhanced immune response compared to animals treated with the vaccine alone. The authors conclude that DEF201 drives an interferon-mediated stimulation of the innate immunity which enhanced the resulting adaptive immunity to the vaccine which cleared the Ebola virus infection and provided complete survival.

“Ebola virus infections have an extremely high case fatality rate and no approved vaccines or treatments exist today for clinical management” said Dr. Gary Kobinger, Chief of Special Pathogens at NML-PHAC, “as such, we are very interested in collaborating with industry partners focused on the advanced development of medical countermeasures. Defyurus’ DEF201 technology provides a wonderful synergy to augment our Ebola vaccine performance.”

“This study confirmed our belief that a combination therapy approach that stimulates both the innate and adaptive immune systems, could rescue animals from lethal Ebola infections” stated, Dr. Jeffrey Turner, President & CEO, Defyurus Inc., “such studies require expertise and facilities that are unique to NML in Canada”.

About Defyurus

Defyurus is a private, life sciences biodefence company that collaborates with military and public health R&D partners in the United States, United Kingdom and Canada to develop broad spectrum anti-viral drugs and immunopotentiators to improve vaccine performance as medical countermeasures to viral threats of military and public health interest. www.defyurus.com

About NML

As Canada’s leading public health infectious disease laboratory, the National Microbiology Laboratory is responsible for the identification, control and prevention of infectious diseases. The NML is located at the Canadian Science Centre for Human and Animal Health, the first facility in the world to have high containment laboratories for human and animal health in one facility. It is recognized as a leading facility in an elite group of centres around the world, equipped with laboratories ranging from biosafety level 2 up to level 4 designed to accommodate the most deadly infectious organisms. www.nml-lnm.gc.ca

###



For further information:

Dr. Jeffrey D. Turner
President & CEO
Tel: (613) 674-1138
info@defyrus.com

Mr. Dana Rath
Chief Financial Officer
Tel: (514) 939-2531
info@defyrus.com